Lugano, Switzerland, June 02, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces its participation in the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting which will be held from 3-7 June.

In alignment with Helsinn’s new Fully Integrated Target Therapy (FITT) strategy in oncology, two abstracts have been accepted for poster presentation.

The first abstract shares results of a preclinical study exploring the brain penetrability of vepafestinib (TAS0953/HM06), Helsinn’s investigational oral treatment targeting rearranged during transfection (RET) abnormalities in solid tumors.

Title: Comparison of TAS0953/HM06 and selpercatinib in RET Fusion-driven Preclinical Disease Models of Intracranial Metastases

  • Author: Igor Odintsov, MD, Memorial Sloan Kettering Cancer Center
  • Session: Central Nervous System Tumors
  • Abstract ID: 2024

The second abstract provides an overview of the ongoing PROOF 301 trial of infigratinib, a kinase inhibitor targeting cancers driven by fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements. Details are as follows:

Title: PROOF 301: a multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement

  • Author: Ghassan K. Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College
  • Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
  • Abstract ID: TPS4171

Sergio Cantoreggi, Helsinn Group Chief Scientific Officer and Head of R&D, commented: “We are excited that the abstracts on two of our investigational products, vepafestinib and infigratinib, have been accepted for presentation at ASCO. In line with our Fully Integrated Targeted Therapy strategy, we are dedicated to progressing our pipeline of products to treat rare oncological diseases. More broadly, we are increasingly convinced of the importance of adequate screening for genetic alterations, through the use of comprehensive biomarker testing, to expand disease treatment options, thus ensuring that patients can receive the most appropriate and targeted treatment.”

Download the PR here:

New data on Helsinn’s oncology pipeline presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022

pdf 230KB

Helsinn Media Contact:

Paola Bonvicini, Group Head of Communication
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
Email: [email protected]

For more information, please visit and follow us on Twitter and LinkedIn